Trial Profile
The Effects of Rasagiline on Cognitive Deficits Associated With Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Over 3 Months
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Rasagiline (Primary)
- Indications Cognition disorders; Parkinson's disease
- Focus Therapeutic Use
- 13 Sep 2011 Results presented at the 15th Congress of the European Federation of Neurological Societies.
- 09 Jun 2011 Results presented at the 15th International Congress of Parkinson's Disease and Movement Disorders.
- 11 Jul 2008 New trial record.